Science News

p21Waf1/Cip1: its paradoxical effect in the regulation of breast cancer.

A new interesting article has been published in Breast Cancer. 2018 Sep 25. doi: 10.1007/s12282-018-0913-1. Review and titled:

p21Waf1/Cip1: its paradoxical effect in the regulation of breast cancer.

Authors of this article are:
Zohny SF Al-Malki AL Zamzami MA Choudhry H.

A summary of the article is shown below:
p21Waf1/Cip1, the cyclin-dependent kinase (CDK) inhibitor belonging to the KIP/CIP family, was initially regarded as a tumor suppressor protein because it was recognized as the chief mediator of p53-dependent cell cycle arrest elicited by DNA damage. Conversely, it has been proposed that p21Waf1/Cip1 may also function as an oncogene because it can inhibit apoptosis. Thus, p21Waf1/Cip1 is regarded as a protein with a dual behavior, as its expression might cause potential benefits or dangerous effects in breast cancer. Consequently, careful planning is required in targeting p21Waf1/Cip1 expression for therapy of breast cancer patients. This review illustrates the discovery and mechanisms of induction of p21Waf1/Cip1. Then, we focus on elucidating the paradoxical effect of p21Waf1/Cip1 expression on human breast carcinogenesis and explaining how the subcellular localization (nuclear or cytoplasmic) of p21Waf1/Cip1 has an impact on both determining its fate as either cell-growth inhibitor or antiapoptotic molecule and, its effect on clinicopathological factors and prognosis of breast cancer patients. Moreover, we explore how the pattern of the p21Waf1/Cip1 could affect the responsiveness of human breast cancer to chemotherapy. Furthermore, the pharmacological approaches to target p21Waf1/Cip1 expression for therapy of breast cancer are clarified.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as: p21Waf1/Cip1;p53;Prognosis;Pharmacological approaches;Breast cancer.

Categories: Science News